



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: UIC0005US.NP  
Inventors: Kumar et al.  
Serial No.: 10/567,958  
Filing Date: Not Yet Assigned  
Examiner: Not Yet Assigned  
Customer No.: 26259  
Group Art Unit: Not Yet Assigned  
Confirmation No.: Not Yet Assigned  
Title: Silencing of TGF-Beta Receptor Type II Expression by siRNA

I, Jane Massey Licata, Registration No. 32,257,  
certify that this correspondence is being deposited  
with the U.S. Postal Service as First Class mail in  
an envelope addressed to the Commissioner for Patents  
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: May 16, 2006

Jane Massey  
Jane Massey Licata, Registration No. 32,257

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R.  
§§1.97-1.98, information relating to the above-identified  
application is hereby disclosed. Inclusion of information in  
this statement is not to be construed as an admission that this  
information is material as that term is defined in 37 C.F.R.  
§1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is attached hereto; or

( ) Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.


Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

(XX) Copies of the PCT Search Report from and Written Opinion Application No. PCT/US04/25984, which corresponds to this U.S. Patent Application are included.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata  
Registration No. 32,257

Date: May 16, 2006

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 02

Form PTO-1449 Modified		Docket No. UIC0005US.NP	Serial No. 10/567,958
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Kumar et al.	
U.S. Department of Commerce		Filing Date Not Yet Assigned	Group Not Yet Assigned

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	BA	Iyer et al., "Targeting TGF $\beta$ Signaling for Cancer therapy", Cancer Biology & Therapy 2005 4:3, 261-266
	BB	Lin et al., "Expression Cloning of the TGF- $\beta$ Type II Receptor, a Functional Transmembrane Serine/Threonine Kinase", Cell 1992 68:775-785
	BC	Tuschl et al., "Selection of siRNA duplexes from the target mRNA sequence", The siRNA user guide April 16, 2003, 6 pages

EXAMINER

DATE CONSIDERED

**U. S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Translation	
				YES	NO
CB	WO 03/070197 A2	8-28-03	PCT	x	

**EXAMINER**

**DATE CONSIDERED**